What is Viva Biotech Holdings?
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
VBIZF · Verdict
Moderate reward · moderate risk
VBIZF stands out on valuation and balance sheet, but watch the volatility signal.
Based on 88% data coverage
VBIZF · Verdict
Above average
Interest covered 6.5×
9% free-cash-flow margin
Weak vs peers
Rev -1.9% CAGR · earnings -16.5%
8% net margin · 6% ROE
Model-based scoring. For information only — not financial advice.
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 724.45M, and a P/E ratio of 34.3x.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.